MENU
IBB
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

IBB stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Oct 25, 2026

iShares Biotechnology ETF (IBB) ETF Analysis: Large-Cap Biotech Anchors a Defensive Growth Portfolio

Key Takeaways

  • IBB, the iShares Biotechnology ETF (exchange-traded fund), tracks the NASDAQ Biotechnology Index and holds roughly 250 U.S.-listed biotechnology and life-sciences companies.
  • The fund is a market-cap-weighted, passively managed vehicle with an expense ratio of 0.44% and an AUM (assets under management) in the range of $10–11 billion.
  • Its portfolio is concentrated in large-cap biotech leaders such as GILD, AMGN, and VRTX, which account for a substantial share of total assets.
  • Over the trailing 30 days the ETF was little changed, drifting roughly 1% lower, while its three-month trend was notably stronger at approximately +10%.
  • The fund's performance reflects a health-care sector environment shaped by interest-rate expectations, clinical data catalysts, and rotation toward large-cap, cash-generative names.
  • Principal opportunities include a steady pipeline of drug approvals and M&A (mergers and acquisitions) activity, while key risks center on regulatory pressure and elevated valuation sensitivity.
  • For additional context on this ticker, explore Price Targets and Forecast on dedicated pages.
  • Investors can also discover real-time trading ideas by exploring Trending AI Robots.

iShares Biotechnology ETF (IBB) Overview

IBB is a passively managed exchange-traded fund that seeks to replicate the performance of the NASDAQ Biotechnology Index, a modified market-capitalization-weighted benchmark of U.S.-listed biotechnology and pharmaceutical companies. The fund invests at least 80% of its assets in the component securities of its underlying index, with the remainder available for futures, options, swaps, and cash equivalents.

The portfolio holds approximately 248–251 securities and carries a net expense ratio of 0.44%. It is anchored by large-cap biotech franchises, with top positions including Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Moderna (MRNA). Other meaningful holdings include Natera (NTRA), Illumina (ILMN), Revolution Medicines (RVMD), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY).

Because the fund is market-cap weighted, its behavior is heavily influenced by its largest, most liquid constituents rather than by smaller clinical-stage names. This concentration in mature, cash-generative franchises tends to moderate volatility relative to the broader, more speculative biotech universe, a structural feature that helps explain the fund's comparatively steady recent trading.

Industry and Thematic Landscape

Biotechnology operates within the broader health-care sector, which is often characterized as a defensive growth area: demand for medicines is relatively inelastic, yet individual companies remain exposed to binary clinical and regulatory outcomes. In the current macroeconomic environment, the sector's outlook is shaped by monetary policy expectations, because biotechnology valuations are sensitive to changes in long-term interest rates used to discount future cash flows.

Structural drivers continue to support the industry. An aging global population, advances in genetic medicine, and expanding pipelines in oncology, immunology, and rare disease create durable long-term demand. At the same time, the competitive landscape is intensifying as large pharmaceutical companies pursue acquisitions of innovative biotech assets, and as pricing and reimbursement scrutiny persists across major markets. These dynamics favor larger, diversified biotech firms with approved products and recurring revenue over pre-revenue developers, reinforcing the relative stability of IBB's large-cap tilt.

Performance and Positioning Snapshot

IBB has been comparatively range-bound over recent weeks. From the closing price roughly 30 days earlier to the most recent completed session, the fund edged lower by approximately 1%, a modest move that reflects subdued trading conditions in the health-care complex rather than any single catalyst. By contrast, the trailing three-month period was stronger, with the fund advancing roughly 10% from its levels roughly a quarter earlier.

This divergence between a muted near-term tape and a firmer quarterly trend points to gradual, trend-driven appreciation rather than sharp directional swings. The quarterly advance was supported by broad strength among large-cap holdings and a market environment in which investors favored profitable, established biotech franchises. Earnings seasons, clinical data readouts, and shifting interest-rate expectations all contributed to periodic volatility, but the fund's heavyweight positions provided ballast that kept overall movement measured.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors search thousands of securities using technical indicators, fundamentals, volatility measures, AI-generated signals, market trends, price patterns, and customizable filters. It is designed to surface trending securities, breakout candidates, and new trading opportunities more efficiently than manual screening, allowing users to focus their research on ideas that match specific criteria. For investors tracking thematic vehicles such as IBB, the screener offers a practical way to compare holdings, monitor momentum, and identify emerging patterns across the biotechnology universe. Consider exploring the AI Screener to complement your own research process.

2026 Outlook and Key Factors to Monitor

Several structural factors are likely to influence IBB through 2026. Interest-rate expectations remain central, as the valuation of long-duration biotech assets is closely tied to the path of monetary policy and bond yields. Inflation trends and the broader macroeconomic environment will also shape risk appetite toward the sector, while the earnings cycles of major holdings such as Gilead, Amgen, and Vertex will remain key drivers of index-level performance.

Investors should also monitor industry developments including the pace of drug approvals, pipeline progress in high-growth areas such as oncology and gene editing, and the level of M&A activity, which has historically acted as a catalyst for the space. Regulatory and pricing policy in major markets, along with capital flows into health-care funds, represent additional variables. On the risk side, concentrated positions in a handful of mega-cap names and sensitivity to headline-driven volatility in clinical-stage constituents remain important considerations. None of these factors should be read as a forecast, but together they frame the themes most likely to shape the fund over the coming months.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for IBB with price predictions
Nov 20, 2026

IBB in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 16, 2026

IBB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 42 cases where IBB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for IBB crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in 276 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 220 of 244 cases where IBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBB as a result. In 74 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for IBB turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

IBB moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF (IBB) ETF is 7.93B. The market cap for tickers in the group ranges from 25.61M to 248.92B. AMGN holds the highest valuation in this group at 248.92B. The lowest valued company is AARD at 25.61M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was -6%. For the same ETF, the average monthly price growth was -6%, and the average quarterly price growth was 18%. INSM experienced the highest price growth at 17%, while UPB experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was 29%. For the same stocks of the ETF, the average monthly volume growth was 25% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 47
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 87
Seasonality Score: 11 (-100 ... +100)
iShares Biotechnology ETF (IBB) ETF Analysis: Large-Cap Biotech Anchors a Defensive Growth Portfolio